Selective serotonin reuptake inhibitors reduce Rankin scores in stroke patients: a Meta-analysis

doi:10.3877/cma.j.issn.1674-0785.2017.16.006

Abstract

Abstract:

Objective

To evaluate whether selective serotonin reuptake inhibitors reduce Rankin scores in stroke patients.

Methods

Related articles published between 1990 and 2015 were searched in MEDLINE, PUBMED, EMBASE, and WOS. The quality of the included studies was evaluated using the Jadad score. Studies with a Jadad score < 4 were included. The patients were divided into two groups: patients who used selective serotonin reuptake inhibitors and those who did not use. Rankin scores were calculated using the modified Rankin scale at 90 days after stroke.

Results

Compared to stroke patients who did not use selective serotonin uptake inhibitors, patients who used selective serotonin reuptake inhibitors had significantly lower Rankin scores (overall: SMD = 0.75, 95% CI: 0.64-0.87, Z = 12.67, P = 0.000; fluoxetine: SMD = 0.44, 95% CI: 0.20-0.68, Z = 3.55, P = 0.000; paroxetine: SMD = 0.82, 95% CI: 0.56-1.08, Z = 6.20, P = 0.000; sertraline: SMD = 0.69, 95% CI: 0.44-0.94, Z = 5.42, P = 0.00; citalopram: SMD = 0.91, 95% CI: 0.64-1.17, Z = 6.72, P = 0.000; escitalopram: SMD = 1.05, 95% CI: 0.75-1.36, Z = 6.78, P = 0.000).

Conclusions

Selective serotonin reuptake inhibitors can reduce rankin scores in stroke patients.

Key words: Selective serotonin inhibitors, Reuptake, Fluoxetine, Paroxetine, Sertraline, Escitalopram

Zhibin Zhang, Li Cao, Jingfeng Sun, Zhihai Xie. Selective serotonin reuptake inhibitors reduce Rankin scores in stroke patients: a Meta-analysis[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(16): 2134-2139.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2017.16.006

https://zhlcyszz.cma-cmc.com.cn/EN/Y2017/V11/I16/2134

Figures/Tables 5

References 23

[1]	Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo- controlled trial [J]. Lancet Neurol, 2011, 10(2): 123-130.
[2]	Lopes R, Alves JC, Rego RG. Trazodone addition to Paroxetine and Mirtazapine in a patient with treatment-resistant depression: the pros and cons of combining three antidepressants [J]. Case Rep Med, 2016, 2016: 5362485.
[3]	Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy [J]. Stroke, 1996, 27(11): 1211-1214.
[4]	Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study [J]. Am J Psychiatry, 2000, 157(3): 351-359.
[5]	Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study [J]. Stroke, 2000, 31(8): 1829-1832.
[6]	Chen WY, Lin FY, Hearn MT. Microcalorimetric studies on the interaction mechanism between proteins and hydrophobic solid surfaces in hydrophobic interaction chromatography: effects of salts, hydrophobicity of the sorbent, and structure of the protein [J]. Anal Chem, 2001, 73(16): 3875-3883.
[7]	Xu J, Narabu T, Mizukubo T, et al. A Molecular Marker Correlated with Selected Virulence Against the Tomato Resistance Gene Mi in Meloidogyne incognita, M. javanica, and M. arenaria [J]. Phytopathology, 2001, 91(4): 377-382.
[8]	Chen W, Zhu G, Wang T, et al. The expression of heat shock protein 70(HSP70) in the cells of rat liver and cardiac muscle in different heat exposure Stages [J]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, 2002, 20(4): 285-288.
[9]	Hama S, Yamashita H, Shigenobu M, et al. Sitting balance as an early predictor of functional improvement in association with depressive symptoms in stroke patients [J]. Psychiatry Clin Neurosci, 2007,61(5): 543-551.
[10]	Wang DZ. Editorial comment-telemedicine: the solution to provide rural stroke coverage and the answer to the shortage of stroke neurologists and radiologists [J]. Stroke, 2003, 34(12): 2957.
[11]	Zhou XS, Fan WM, Zhang YX. Fermentation behaviors of recombinant Pichia pastoris under inhibited methanol concentration [J]. Sheng Wu Gong Cheng Xue Bao, 2003, 19(5): 618-622.
[12]	Liu Y, Barks JD, Xu G, et al. Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats [J]. Stroke, 2004, 35(6): 1460-1465.
[13]	Ye H, Yan JT, Shao JM, et al. A case-control study on the relationship between stroke and plasma homocysteine level and the mutation of MTHFR gene [J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2004, 25(11): 958-961.
[14]	Chen JC, Liang CC, Shaw FZ. Facilitation of sensory and motor recovery by thermal intervention for the hemiplegic upper limb in acute stroke patients: a single-blind randomized clinical trial [J]. Stroke, 2005, 36(12): 2665-2669.
[15]	He ML, Gonzalez-Iglesias AE, Tomic M, et al. Release and extracellular metabolism of ATP by ecto-nucleotidase eNTPDase 1-3 in hypothalamic and pituitary cells [J]. Purinergic Signal, 2005, 1(2): 135-144.
[16]	Xie RJ, Hirosaki N, Mitomo M, et al. Strong green emission from alpha-SiAlON activated by divalent ytterbium under blue light irradiation [J]. J Phys Chem B, 2005, 109(19): 9490-9494.
[17]	Li Y, Zhou L, Coulter D, Gao E, et al. Prospective cohort study of the association between use of low-dose oral contraceptives and stroke in Chinese women [J]. Pharmacoepidemiol Drug Saf, 2006, 15(10): 726-734.
[18]	Liu LS, Caguioa ES, Park CG, et al. Asia-Pacific Consensus Conference on Stroke Prevention in HypertensivePatients. Reducing stroke risk in hypertensive patients: Asian Consensus Conference recommendations [J]. Int J Stroke, 2006, 1(3): 150-157.
[19]	Xu Z, Croslan DR, Harris AE, et al. Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke [J]. J Cereb Blood Flow Metab, 2006, 26(4): 527-535.
[20]	Kong SY, Li QF, Yang J, et al. The effect of butylphthalide on expression of NGF and BDNF in ischemia stroke tissue of rat cerebrum [J]. Sichuan Da Xue Xue BaoYi Xue Ban, 2007, 38(3): 400-403, 407.
[21]	Xu B, Zhou WY, Zhang SJ. Observation on effect of Wuling Capsule in treating poststroke depression [J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2007,27(7): 640-642.
[22]	Li LT, Wang SH, Ge HY, et al. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus(FEWP) and fluoxetine on post-stroke depression [J]. J Altern Complement Med, 2008, 14(7): 841-846.
[23]	Acler M, Robol E, Fiaschi A, et al. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients [J]. J Neurol, 2009, 256(7): 1152-1158.

研究者	年份	M试验组	S试验组	N试验组	M对照组	S对照组	N对照组	药物名	JAD评分
Dam等^[3]	1996	61.9	13	16	54.1	21.1	16	弗西汀	5
Robinson等^[4]	2000	60.5	10.8	13	63.1	8.2	15	舍曲林	5
?	?	59.2	11.6	14	56.2	7.74	13	艾司西酞普兰	?
?Wiart?等^[5]	2000	87.4	22.8	16	88.7	25.3	15	艾司西酞普兰	5
Chen等^[6]	2001	79.31	8.94	19	71.56	9.41	18	弗西汀	5
?Xu?等^[7]	2001	73	4.4	26	67	4.1	27	西酞普兰	5
Chen等^[8]	2002	61	12.2	24	51.5	10.3	20	帕罗西汀	5
Cheng等^[9]	2003	26.38	14.2	25	29.15	17.38	32	弗西汀	5
Wang^[10]	2003	75	4.2	51	61	6.9	47	艾司西酞普兰	5
Zhou等^[11]	2003	27.8	7.1	28	32.5	7.8	26	舍曲林	5
Liu等^[12]	2004	70.3	10.74	30	64.33	7.7	30	艾司西酞普兰	5
Ye等^[13]	2004	78.75	14.19	30	50.26	13.4	30	帕罗西汀	5
Chen等^[14]	2005	65.76	5.92	40	51.6	7.32	38	帕罗西汀	5
He等^[15]	2005	84.26	8.41	27	78.33	15.01	27	帕罗西汀	5
?Xie?等^[16]	2005	88.7	7.9	65	79.8	4.5	65	舍曲林	5
Li等^[17]	2006	64.36	8.23	50	59.17	9.02	49	西酞普兰	5
Liu等^[18]	2006	64.4	12.2	30	35.4	9.1	30	西酞普兰	5
?Xu?等^[19]	2006	27.63	4.81	28	32.81	4.13	29	帕罗西汀	5
Kong等^[20]	2007	60.4	12.5	37	52.3	13.5	36	弗西汀	5
?Xu?等^[21]	2007	64.4	8.23	36	56.9	0.68	36	舍曲林	5
Li等^[22]	2008	40.8	3.7	58	38.4	5.8	28	弗西汀	5
?Acler?等^[23]	2009	10	82	28	10	75	25	西酞普兰	5

研究者	年份	M试验组	S试验组	N试验组	M对照组	S对照组	N对照组	药物名	JAD评分
Dam等^[3]	1996	61.9	13	16	54.1	21.1	16	弗西汀	5
Robinson等^[4]	2000	60.5	10.8	13	63.1	8.2	15	舍曲林	5
?	?	59.2	11.6	14	56.2	7.74	13	艾司西酞普兰	?
?Wiart?等^[5]	2000	87.4	22.8	16	88.7	25.3	15	艾司西酞普兰	5
Chen等^[6]	2001	79.31	8.94	19	71.56	9.41	18	弗西汀	5
?Xu?等^[7]	2001	73	4.4	26	67	4.1	27	西酞普兰	5
Chen等^[8]	2002	61	12.2	24	51.5	10.3	20	帕罗西汀	5
Cheng等^[9]	2003	26.38	14.2	25	29.15	17.38	32	弗西汀	5
Wang^[10]	2003	75	4.2	51	61	6.9	47	艾司西酞普兰	5
Zhou等^[11]	2003	27.8	7.1	28	32.5	7.8	26	舍曲林	5
Liu等^[12]	2004	70.3	10.74	30	64.33	7.7	30	艾司西酞普兰	5
Ye等^[13]	2004	78.75	14.19	30	50.26	13.4	30	帕罗西汀	5
Chen等^[14]	2005	65.76	5.92	40	51.6	7.32	38	帕罗西汀	5
He等^[15]	2005	84.26	8.41	27	78.33	15.01	27	帕罗西汀	5
?Xie?等^[16]	2005	88.7	7.9	65	79.8	4.5	65	舍曲林	5
Li等^[17]	2006	64.36	8.23	50	59.17	9.02	49	西酞普兰	5
Liu等^[18]	2006	64.4	12.2	30	35.4	9.1	30	西酞普兰	5
?Xu?等^[19]	2006	27.63	4.81	28	32.81	4.13	29	帕罗西汀	5
Kong等^[20]	2007	60.4	12.5	37	52.3	13.5	36	弗西汀	5
?Xu?等^[21]	2007	64.4	8.23	36	56.9	0.68	36	舍曲林	5
Li等^[22]	2008	40.8	3.7	58	38.4	5.8	28	弗西汀	5
?Acler?等^[23]	2009	10	82	28	10	75	25	西酞普兰	5

Please choose a citation manager

Content to export